Genmab B.V.

14 patents currently held · Updated Nov 14, 2026

4 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Apr 2033

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Oct 26, 2027
The maintenance fee for Humanised ANTI-CD52 Antibodies (US 9,321,841) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.
1 fee due Nov 12, 2027
The maintenance fee for ANTI-DR5 Family Antibodies, Bispecific or Multivalent ANTI-DR5 Family Antibodies and Methods of Use Thereof (US 10,647,774) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,321,841	Humanised ANTI-CD52 Antibodies In force Term ends Apr 4, 2033 · High confidence	In force	Term ends Apr 4, 2033	High confidence
US 9,611,327	ANTI-DR5 Family Antibodies, Bispecific or Multivalent ANTI-DR5 Family Antibodies and Methods of Use Thereof In force Term ends Oct 31, 2033 · High confidence	In force	Term ends Oct 31, 2033	High confidence
US 12,049,512	Antibody Variants and Uses Thereof In force Term ends Jan 4, 2034 · High confidence	In force	Term ends Jan 4, 2034	High confidence
US 11,180,572	Dimeric Protein with Triple Mutations In force Term ends Feb 13, 2034 · High confidence	In force	Term ends Feb 13, 2034	High confidence
US 10,759,867	Antibody Variants and Uses Thereof In force Term ends Mar 5, 2034 · High confidence	In force	Term ends Mar 5, 2034	High confidence
US 10,647,774	ANTI-DR5 Family Antibodies, Bispecific or Multivalent ANTI-DR5 Family Antibodies and Methods of Use Thereof In force Term ends Apr 23, 2034 · High confidence	In force	Term ends Apr 23, 2034	High confidence
US 10,882,913	ANTI-DR5 Antibodies and Methods of Use Thereof In force Ends no later than Dec 1, 2036 · Medium confidence	In force	Ends no later than Dec 1, 2036	Medium confidence
US 12,577,316	Methods of Use of ANTI-CD37 Antibodies, Monoclonal ANTI-CD37 Antibodies In force Term ends Apr 3, 2038 · Medium confidence	In force	Term ends Apr 3, 2038	Medium confidence
US 12,247,080	ANTI-DR5 Antibodies and Methods of Use Thereof In force Term ends Jun 5, 2038 · High confidence	In force	Term ends Jun 5, 2038	High confidence
US 12,173,076	Polypeptide Variants and Uses Thereof In force Term ends Jan 20, 2039 · High confidence	In force	Term ends Jan 20, 2039	High confidence

10 of 14 patents shown.

Pro members see all 14.

Pro members: see all 14 patents

Also on record, not counted in the 14: 4 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 pending · 17 abandoned

List them